| Basics |
Bio-Path Holdings, Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.
|
| IPO Date: |
April 1, 2008 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.15 | 4.05%
|
| Avg Daily Range (30 D): |
$0.01 | 8.61%
|
| Avg Daily Range (90 D): |
$0.02 | 8.02%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.44M |
| Avg Daily Volume (30 D): |
.02M |
| Avg Daily Volume (90 D): |
.21M |
| Trade Size |
| Avg Trade Size (Sh.): |
225 |
| Avg Trade Size (Sh.) (30 D): |
1,383 |
| Avg Trade Size (Sh.) (90 D): |
462 |
| Institutional Trades |
| Total Inst.Trades: |
56 |
| Avg Inst. Trade: |
$2.12M |
| Avg Inst. Trade (30 D): |
$.98M |
| Avg Inst. Trade (90 D): |
$.98M |
| Avg Inst. Trade Volume: |
.01M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.97M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
1.21K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-2.33
|
$-.07
|
$-4.12
|
|
Diluted EPS
|
$-2.33
|
$-.07
|
$-4.12
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -12.75M
|
$ -2.75M
|
$ -9.89M
|
|
Operating Income / Loss
|
$ -11.54M
|
$ -2.63M
|
$ -11.99M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Feb 23, 2024:
1:20
|
|
Jan 18, 2019:
1:20
|
|
Feb 09, 2018:
1:10
|
|
